HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4945 Pregnenolone monosulfate sodium Pregnenolone monosulfate sodium, a sodium salt form of pregnenolone monosulfate, is an active neurosteroid and a precursor of all steroid hormones. It functions act as a potent endogenous allosteric signal-specific inhibitor of CB1 receptors, reducing psychoactive effects associated with Δ9-tetrahydrocannabinol (THC). Oct 10 2024
E4652 ZX703 ZX703 is a proteolysis targeting chimera (PROTAC), that is a degrader of GPX4 through the ubiquitin-proteasome and the autophagy-lysosome with a DC50 of 0.315 µM. It induces the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis cancer cells. Oct 10 2024
E1301 Imlunestrant Imlunestrant(LY3484356) is a potent, orally bioavailable selective estrogen receptor degrader (SERD) that functions as a pure antagonist of estrogen receptor alpha (ERα). It inhibits ER-dependent gene transcription and cell proliferation, resulting in sustained suppression of estrogen-driven growth in ER-positive cells. Oct 10 2024
E4715 SB-328437 SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema. Oct 10 2024
E1967 ORIC-944 ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit. It exhibits anti-tumor activity in vivo prostate cancer models. Oct 07 2024
E4947 Estrone sulfate sodium Estrone sulfate (Estrone 3-sulfate sodium salt, Premarin), an inactive form of estrogen, serves as a major circulating estrogen in the plasma. It is converted into the active form, estrone (E1), through the action of steroid sulfatase (STS. Estrone sulfate is commonly used in breast cancer research. Oct 07 2024
E4692 THZ-P1-2 THZ-P1-2 is an inhibitor of PI5P4K, which covalently binds to cysteines on a disordered loop in PI5P4Kα/β/γ. It inhibits PI5P4Kα kinase activity with an IC50 of 190 nM and disrupts autophagy by impairing autophagosome clearance and increasing TFEB nuclear localization. Oct 07 2024
E1831 FX-909 FX-909 is an orally available inverse agonist and inhibitor of the transcription factor (TF) peroxisome proliferator activated receptor gamma (PPARG, PPARγ) ), which exhibits anti-tumor activity in vivo. Oct 07 2024
E4958 cis-Bac430 Cis-Bac430 plays a role in mediating the movement of anti-tumor CD8+cells from the periphery to the tumor site,thus enhancing the anti-tumor effect of an immune checkpoint inhibitor. Sep 29 2024
E4886 HS-10296 hydrochloride HS-10296 hydrochloride(Almonertinib (hydrochloride), HS-10296 HCl) is an irreversible, third-generation inhibitor of EGFR tyrosine kinase that demonstrates high selectivity for EGFR-sensitizing mutations, T790M resistance mutation. It exhibits inhibitory activity against T790M, T790M/L858R, and T790M/Del19, with IC50 of 0.37 nM, 0.29 nM, and 0.21 nM, respectively. It also exhibits anti-tumor activity. Sep 28 2024
E1973 R16 R16(NSC29869, Nrf2-IN-3) is an inhibitor of NRF2 (nuclear factor erythroid 2-related factor 2) that selectively binds KEAP1 mutants and restores their NRF2-inhibitory function by repairing the disrupted KEAP1/NRF2 interactions. It significantly enhances the sensitivity of KEAP1-mutated tumor cells to cisplatin and gefitinib. Sep 28 2024
E1349 TNG908 TNG908 is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model. Sep 28 2024
E1842 Palazestrant Palazestrant(OP-1250) is an orally bioavailable complete antagonist of estrogen receptor (ER) that blocks ER activity. It exhibits antiproliferative and antitumor activity in ER-positive (ER+) breast cancer models. Sep 28 2024
E4893 Flecainide hydrochloride Flecainide hydrochloride, an antiarrhythmic drug, is a blocker of hydrophilic sodium channels with a pKa of 9.3. At pH 7.4. It also inhibits the ryanodine receptor (RyR2), reducing spontaneous calcium release from the sarcoplasmic reticulum. Sep 28 2024
E4862 Pimethixene Pimethixene(Calmixen, Pimetixene) is a highly potent and non-selective antagonist of the 5-HT2B receptor, with a pKi of 10.44. It also functions as an antihistamine and anticholinergic agent, and is a highly potent multi-target antagonist with antagonistic effects on multiple receptors. Sep 28 2024
E4900 Enalapril Enalapril(Eletriptan, Amprace, Vaseretic) is an inhibitor of angiotensin-converting enzyme (ACE), primarily used to treat hypertension, heart failure, and asymptomatic left ventricular dysfunction. It also attenuates frailty in aging mice. Sep 26 2024
E4954 Demeclocycline Demeclocycline(Demethylchlortetracycline (DMCT), Ledermycin) is a bacteriostatic antibiotic from the tetracycline class, that induces diuresis and can cause nephrogenic diabetes insipidus. It also manages the syndrome of inappropriate antidiuretic hormone secretion (SIADH) by restoring normal plasma sodium levels and permitting unrestricted water intake. Sep 26 2024
E4834 12-Crown-4 12-crown-4(EOCT, Ethylene oxide cyclic tetramer) is an effective phase-transfer catalyst and complexing agent for lithium, facilitating the dissolution of lithium bis(trifluoromethanesulfonyl)imide (LiTFSI) without requiring acetonitrile. It selectively binds to lithium ions and forms stable complexes, significantly improving electrolyte conductivity in lithium batteries, and positively influencing ion mobility and overall battery performance. Sep 25 2024
E4701 CMP-5 CMP5 is a potent and selective small molecule inhibitor of PRMT5. It is found to selectively block S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. It also exhibit potential for research into treatment for EBV+ lymphomas and other B-cell NHL subtypes. Sep 25 2024
E4687 NIBR-LTSi NIBR-LTSi is a selective small-molecule inhibitor of LATS kinase . It agonizes YAP signaling and promotes tissue regeneration in vitro and in vivo, supporting future research on the regenerative potential of the YAP/Hippo pathway. Sep 25 2024